Lilly lifts earnings forecast as newer drugs provide boost

Eli Lilly and Co topped Wall Street estimates for third-quarter profit on Tuesday and raised its yearly earnings target, led by stronger demand for its newer drugs such as diabetes treatment Trulicity and psoriasis medicine Taltz.

Powered by WPeMatico

Scroll to top